DadFinStart your free week
DadFin › Stocks › Healthcare › ENGN

enGene Therapeutics Inc. (ENGN) stock score

Healthcare · Biotechnology · Canada

$1.89 ▼ -21.58% today

62.2
Dad Score, out of 100
middling

enGene Therapeutics Inc. (ENGN) is a Biotechnology company in the Healthcare sector, listed in Canada. On DadFin's weekly run it scores 62.2 out of 100 on the Dad Score, a middling reading that places the business ahead of 62% of the 5,684 US and Canadian stocks DadFin fully scores. Inside Healthcare it ranks #306 of 956. Its strongest axes are price action, conviction and liquidity; its weakest are valuation and quality.

Scores from the run of Nov 15, 2026. The Dad Score answers one question: how good is this business, measured against its own sector. How it is built →

The eight axes

Valuation
Below average
Quality
Weak
Growth
Below average
Price action
Strong
Risk
Below average
Conviction
Strong
Liquidity
Above average
Macro
Above average

Each axis is ranked inside the stock's own sector. Subscribers see the percentile and every input behind each bar.

Key numbers

P/E (trailing)—
P/E (forward)-1.5×
Dividend yield0.00%
Return on capital-60.3%
Operating margin0.0%
Revenue growth (YoY)+0.0%
FCF yield-74.8%
Net debt / EBITDA3.00×
Piotroski F-Score2 / 9
52-week change-70.1%
Market cap$162M
Next earningsDec 22, 2026

What subscribers see on ENGN

Start your free weekSubscriber? Open the full research →

Biotechnology peers

StockCompanyDad ScoreBandMarket cap
VRTXVertex Pharmaceuticals Incorporate75.0good$136.6B
REGNRegeneron Pharmaceuticals, Inc.98.6strong$98.8B
MRNAModerna, Inc.31.8weak$90.4B
ARGXargenx SE86.7strong$60.4B
ONCBeOne Medicines AG95.0strong$47.6B
RPRXRoyalty Pharma plc98.2strong$39.9B
RVMDRevolution Medicines, Inc.44.8middling$37.3B
GMABGenmab A/S63.2middling$31.7B

Prices from DadFin's live feed (refreshed about every 30 minutes in the session); scores from the weekly run of Nov 15, 2026. Fundamentals as reported in the latest filings. Research, not investment advice.